Protagonist Therapeutics CMO Sells Shares in Major Transaction
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1h ago
0mins
Source: Fool
- Executive Stock Sale: Protagonist Therapeutics' Chief Medical Officer Arturo Molina sold 9,514 shares on January 20, 2026, for approximately $784,700, marking his largest direct market sale to date, surpassing his previous maximum of 2,712 shares, indicating confidence in the market.
- Shareholding Status: Post-transaction, Molina retains 97,266 shares valued at $8.11 million, demonstrating his ongoing investment in the company, although the sale was primarily for tax withholding purposes.
- Company Financial Overview: Protagonist Therapeutics boasts a market capitalization of $5.11 billion, with a 120.48% stock price increase over the past year, reflecting strong market expectations for future growth, particularly as it expands its clinical trial pipelines.
- Analyst Rating Support: While Molina's sale should not influence investment decisions, the majority of Wall Street analysts rate the company as a “strong buy,” and its high price-to-earnings ratio of 113.68 suggests optimistic growth expectations from the market.
Get Free Real-Time Notifications for Any Stock
Monitor tickers like PTGX with instant alerts to capture every critical market movement.
Sign up for free to build your custom watchlist and receive professional-grade stock notifications.
Analyst Views on PTGX
Wall Street analysts forecast PTGX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PTGX is 94.54 USD with a low forecast of 65.00 USD and a high forecast of 115.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
13 Analyst Rating
12 Buy
1 Hold
0 Sell
Strong Buy
Current: 79.730
Low
65.00
Averages
94.54
High
115.00
Current: 79.730
Low
65.00
Averages
94.54
High
115.00
About PTGX
Protagonist Therapeutics, Inc. is a biopharmaceutical company focused on peptide therapeutics. The Company’s clinical programs fall into two categories of diseases: hematology and blood disorders, and inflammatory and immunomodulatory diseases. Its two peptides derived from its proprietary discovery technology platform, rusfertide and icotrokinra, are in advanced Phase III clinical development. Its rusfertide (PTG-300) is an injectable hepcidin mimetic in development for the potential treatment of polycythemia vera (PV) and other blood disorders. Icotrokinra, an orally delivered IL-23R specific antagonist for the potential treatment of psoriasis, psoriatic arthritis (PsA), ulcerative colitis and inflammatory bowel disease (IBD) indications. The Company also has a pre-clinical stage oral drug discovery program addressing clinically and commercially validated targets, including the IL-17 oral peptide antagonist PN-881, an oral hepcidin program, and an oral obesity program.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Protagonist Therapeutics CMO Sells Shares in Major Transaction
- Executive Stock Sale: Protagonist Therapeutics' Chief Medical Officer Arturo Molina sold 9,514 shares on January 20, 2026, for approximately $784,700, marking his largest direct market sale to date, surpassing his previous maximum of 2,712 shares, indicating confidence in the market.
- Shareholding Status: Post-transaction, Molina retains 97,266 shares valued at $8.11 million, demonstrating his ongoing investment in the company, although the sale was primarily for tax withholding purposes.
- Company Financial Overview: Protagonist Therapeutics boasts a market capitalization of $5.11 billion, with a 120.48% stock price increase over the past year, reflecting strong market expectations for future growth, particularly as it expands its clinical trial pipelines.
- Analyst Rating Support: While Molina's sale should not influence investment decisions, the majority of Wall Street analysts rate the company as a “strong buy,” and its high price-to-earnings ratio of 113.68 suggests optimistic growth expectations from the market.
Continue Reading
Protagonist Therapeutics Executive Sells Shares
- Executive Sell-off: Arturo Molina, Chief Medical Officer of Protagonist Therapeutics, sold 9,514 shares on January 20, 2026, generating approximately $784,700 at a price of $82.48 per share, reducing his holdings from 106,780 to 97,266 shares, representing an 8.91% decrease.
- Market Reaction Analysis: Although Molina's sale was primarily for tax withholding purposes, the majority of Wall Street analysts rate Protagonist's stock as a 'strong buy', with a high price-to-earnings ratio of 113.68, indicating strong growth expectations from the market.
- Clinical Trial Progress: At the early January 2026 J.P. Morgan Healthcare Conference, Protagonist highlighted significant expansion in its clinical trial pipelines, particularly with two key pharmaceutical products reaching advanced clinical development stages, backed by major firms like Johnson & Johnson.
- Stock Performance Review: Protagonist's stock soared approximately 123% in 2025, and with robust support from Wall Street and institutional investors, it appears to be an ideal option for those seeking portfolio exposure in the medical field.
Continue Reading